Increased Calcineurin A Expression Is Associated with a Lower Relapse-Free Survival Rate after Colorectal Cancer Surgery

Objective: Increased expression of calcineurin in colorectal cancer (CRC) has been reported. Although the oncogenic function has been suggested, the clinical relevance is still unclear. We herein studied calcineurin expression as a prognostic biomarker in patients receiving curative surgery for stages I-III CRC. Methods: In 121 patients with stages I-III CRC treated at Hiroshima University between 1997 and 2003, calcineurin A expression was examined using immunohistochemistry (IHC) staining of surgical specimens. Specimens were considered positive for calcineurin A if any IHC-stained cells were observed within the carcinomatous area, and clinicopathological characteristics and survival outcomes were compared between IHC-positive and -negative groups. Results: Calcineurin A was preferentially expressed in the cytoplasm of cancer cells, and a median of 8% of the cells (range: 0-80%; interquartile range: 0-22.5%) were stained within the carcinomatous areas. Of 121 cases, 81 were determined as IHC positive while 40 were determined to be negative. Positive expression of calcineurin A, as well UICC-TNM stage, was associated with low relapse-free survival (RFS) rates in multivariate analyses (hazard ratio = 2.92; 95% CI: 1.27-7.92; p = 0.010). Conclusion: Increased calcineurin A expression is associated with lower RFS rates and may have clinical value in predicting recurrence.

[1]  Matthew H Bailey,et al.  NFATc1 Promotes Prostate Tumorigenesis and Overcomes PTEN Loss-Induced Senescence , 2015, Oncogene.

[2]  M. Kara,et al.  Cancer Screening of Renal Transplant Patients Undergoing Long-Term Immunosuppressive Therapy. , 2015, Transplantation proceedings.

[3]  M. O’connell,et al.  Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials. , 2014, The Lancet. Oncology.

[4]  F. Hsiao,et al.  Epidemiology of post-transplant malignancy in Asian renal transplant recipients: a population-based study , 2014, International Urology and Nephrology.

[5]  H. Ueno,et al.  Characterization of Perineural Invasion As a Component of Colorectal Cancer Staging , 2013, The American journal of surgical pathology.

[6]  Hui Cheng,et al.  Calcineurin/NFATc1 Pathway Contributes to Cell Proliferation in Hepatocellular Carcinoma , 2012, Digestive Diseases and Sciences.

[7]  S. Waldman,et al.  Molecular staging individualizing cancer management , 2012, Journal of surgical oncology.

[8]  Masahiro Yoshida,et al.  Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer , 2012, International Journal of Clinical Oncology.

[9]  M. Hou,et al.  Molecular detection of persistent postoperative circulating tumour cells in stages II and III colon cancer patients via multiple blood sampling: prognostic significance of detection for early relapse , 2011, British Journal of Cancer.

[10]  B. Dieckgraefe,et al.  REG1A expression is a prognostic marker in colorectal cancer and associated with peritoneal carcinomatosis , 2008, International journal of cancer.

[11]  E. Carey,et al.  Do patients need more frequent colonoscopic surveillance after liver transplantation? , 2008, Transplantation proceedings.

[12]  Q. Wei,et al.  Overexpression of calcineurin B subunit (CnB) enhances the oncogenic potential of HEK293 cells , 2008, Cancer science.

[13]  M. Mutch.  Molecular profiling and risk stratification of adenocarcinoma of the colon , 2007, Journal of surgical oncology.

[14]  J. Casal,et al.  A Proteomics Analysis of Cell Signaling Alterations in Colorectal Cancer*S , 2007, Molecular & Cellular Proteomics.

[15]  T. Gress,et al.  Overexpression of c‐myc in pancreatic cancer caused by ectopic activation of NFATc1 and the Ca2+/calcineurin signaling pathway , 2006, The EMBO journal.

[16]  Rajendra K. Sharma,et al.  Increased expression of calcineurin in human colorectal adenocarcinomas , 2005, Journal of cellular biochemistry.

[17]  Young Bae Kim,et al.  Thymidylate synthase gene polymorphism as a prognostic factor for colon cancer , 2005, Journal of Gastrointestinal Surgery.

[18]  M. Orditura,et al.  Prognostic Value of p27, p53, and Vascular Endothelial Growth Factor in Dukes A and B Colon Cancer Patients Undergoing Potentially Curative Surgery , 2004, Diseases of the colon and rectum.

[19]  M. Somerfield,et al.  American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  P. Catalano,et al.  Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M E Hammond,et al.  Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. , 2000, Archives of pathology & laboratory medicine.

[22]  P. Mertz,et al.  Calcineurin: form and function. , 2000, Physiological reviews.

[23]  G. Crabtree.  Generic Signals and Specific Outcomes Signaling through Ca2+, Calcineurin, and NF-AT , 1999, Cell.

[24]  K. Arai,et al.  Signalling into the T-cell nucleus: NFAT regulation. , 1998, Cellular signalling.

[25]  C. Ratto,et al.  Prognostic factors in colorectal cancer , 1998, Diseases of the colon and rectum.

[26]  Hao Ren,et al.  Regulation of the Calmodulin-stimulated Protein Phosphatase, Calcineurin* , 1998, The Journal of Biological Chemistry.

[27]  Tnm.  The tnm classification of malignant tumors , 1988 .

[28]  C. Dukes,et al.  The classification of cancer of the rectum , 1980 .

[29]  C. Klee,et al.  Calcineurin: a calcium- and calmodulin-binding protein of the nervous system. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[30]  F. R. Watson,et al.  Cancer of the colon: the influence of the no-touch isolation technic on survival rates. , 1967, Annals of surgery.

[31]  D. Sargent,et al.  Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. , 2015, Gastroenterology.

[32]  Masahiro Yoshida,et al.  Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer , 2011, International Journal of Clinical Oncology.

[33]  増尾 貴成.  Cyclosporine A inhibits colorectal cancer proliferation probably by regulating expression levels of c-Myc, p21[WAF1/CIP1] and proliferating cell nuclear antigen , 2010 .

[34]  C. Compton,et al.  The Prognosis of T3N0 Colon Cancer Is Dependent on the Number of Lymph Nodes Examined , 2003, Annals of Surgical Oncology.

[35]  P. Hogan,et al.  Transcription factors of the NFAT family: regulation and function. , 1997, Annual review of immunology.

[36]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.